Human papilloma virus vaccination: practical guidelines


  • Kiran Yadav Department of Gynaecology and Gynaec-oncology, Medanta, Gurgaon, Haryana
  • Kaushal Yadav Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
  • Sabhyata Gupta Department of Gynaecology and Gynaec-oncology, Medanta, Gurgaon, Haryana


HPV vaccination, Carcinoma cervix, Cancer vaccination


Cervical cancer has a long latency period and established role of HPV lead to interest in development of HPV vaccine. Main goal of HPV vaccination is to decrease cervical cancer incidence. There are two vaccines available, for the prevention of HPV infection - gardasil and cervarix. Gardasil is quadrivalent and cervarix is bivalent. The FDA has approved gardasil in 2006 and cervarix in 2009 based on their efficacy in phase 3 trails. When recommending HPV immunization of females, it should be offered to girls 11 to 12 years of age, but can be administered as early as nine years. Catch-up vaccination should be offered for females aged 13 to 26 years who have not been previously vaccinated. HPV immunization is not effective in clearing cytological evident disease or HPV infection that is already present and it does not provide immunization for serotypes other than included in vaccine. Cervical cancer screening is recommended to continue as per guidelines.


Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401:70.

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12.

International Agency for Research on Cancer (IARC). Monographs on the evaluation of carcinogenic risks to humans. In: IARC, eds. Human Papillomaviruses. Volume 64. Lyon (France): IARC; 1995: 1-409.

Hampl M, Sarajuuri H, Wentzensen N, Bender HG, Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynaecol. 2006;108:1361.

De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124:1626.

Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis. 2003;36:1397.

Anon. A human papillomavirus vaccine. Med Lett Drugs Ther. 2006;48:65.

Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102:325.

Cervarix--a second HPV vaccine. Med Lett Drugs Ther. 2010;52:37.

Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006;24:5571.

Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247.

GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009;374:1975.

Garland SM, Hernandez-Avila M, Wheelar CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine aginst human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928.

CERVARIX. Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant. Vaccines and Related Biological Products Advisory Committee (VRBPAC), Briefing Document, 2009. Available at: Accessed 12 February 2013.

Sow PS, Watson- Jones D, Kivat N, Changalucha J, Mbaye KD, Brown J, et al. Safety and immunogenicity of human pailloma virus-16/18 ASO4-adjuvanted vaccine, a randomized trial in 10-25 years old HIV seronegative African girls and young women. J Infect Dis. 2013;207:1753.

Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus like particle vaccine containing ASO4 adjuvant. J Adolesc Health 2007;40:564.

Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the the immunogenicity and safety of cervarix and gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009;5:705.

Lin SW, Gosh A, Porras C, Markt SC, Rodriguez AC, Schiffman M, et al. HPV 16 seropositivity and subsequent HPV infection risk in a naturally infected population: comparison of serological assays. PloS One. 2013;8:e53067.

Safaein M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, et al. Epidemiological study of anti-HPV 16/18 seropositivity and subsequent risk of HPV 16 and 18 infection. J Natl Cancer Inst. 2010;102:1653.

FURTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high grade cervical lesions. N Engl J Med. 2007;356:1915.

Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human pappilomavirus (HPV)-16/18 ASO4-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA); final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301.

National Center for Immunization and Respiratory Diseases. General recommendations on immunization: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2011;60:1.

Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, et al. American cancer society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57:7.

Centers for Disease Control and Prevention (CDC). advisory committee on immunization practices (ACIP) recommended immunization schedules for persons aged 0 through 18 years and adults aged 19 years and older - United States, 2013. MMWR Surveill Summ. 2013;62(Suppl 1):1.

Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59:626.

Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13-17 years - United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61:671.

Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103:1444.

Frazer IH, Cox JT, Mayeaux EJ Jr, Franco EL, Moscicki AB, Palefsky JM, et al. Advances in prevention of cervical cancer and other human papillomavirus-related diseases. Paediatr Infect Dis J. 2006;25:S65.

American Cancer Society. Cancer facts and figures, 2004. Available at: Accessed 27 March 2014.




How to Cite

Yadav, K., Yadav, K., & Gupta, S. (2017). Human papilloma virus vaccination: practical guidelines. International Journal of Research in Medical Sciences, 2(4), 1799–1803. Retrieved from